Backup - Revision history

Shweta.mittal@dolcera.com: /* Methodology */

2012-02-16T13:47:31Z

‎Methodology

Shweta.mittal@dolcera.com: /* Methodology */

2012-02-16T13:45:55Z

‎Methodology

Shweta.mittal@dolcera.com: /* Methodology */

2012-02-16T13:45:25Z

‎Methodology

Shweta.mittal@dolcera.com: /* Methodology */

2012-02-16T13:44:27Z

‎Methodology

Shweta.mittal@dolcera.com: /* Methodology */

2012-02-16T13:38:29Z

‎Methodology

Shweta.mittal@dolcera.com: /* Advantage of Mergers and Acquisitions */

2012-02-16T13:37:43Z

‎Advantage of Mergers and Acquisitions

Shweta.mittal@dolcera.com: /* Methodology */

2012-02-16T13:34:06Z

‎Methodology

Shweta.mittal@dolcera.com: /* Methodology */

2012-02-16T13:33:22Z

‎Methodology

Shweta.mittal@dolcera.com: /* Methodology */

2012-02-16T13:31:48Z

‎Methodology

Shweta.mittal@dolcera.com: /* Bioteque Corp. */

2012-02-16T13:26:06Z

‎Bioteque Corp.

@@ Line 124: / Line 124: @@
 |}<br clear="all">
+'''Note:''' Data for Geographical segment, R&D expenditure and Technology focus has been masked.
 {|align="center"

@@ Line 44: / Line 44: @@
 <br/>
-{|border="2" cellspacing="0" cellpadding="4" width="100%" align="center"
+{|border="2" cellspacing="0" cellpadding="4" width="80%" align="center"
 |align = "center" bgcolor = "#4F81BD"|<font color="#FFFFFF">'''Company'''</font>
 |align = "center" bgcolor = "#4F81BD"|<font color="#FFFFFF">'''Headquartered'''</font>

@@ Line 41: / Line 41: @@
 * '''Step 3''': Once the large, and established players were eliminated, companies were compared based on various parameters and rated on the scale of 5 to identify the best target. Please check the following table and dashboard:
 **Number of potential target companies: 6
 {|border="2" cellspacing="0" cellpadding="4" width="100%" align="center"

@@ Line 39: / Line 39: @@
 **Number of (small) companies of interest left: 6
-* '''Step 3''': Once the large, and established players were eliminated, companies were compared based on various parameters and rated on the scale of 5 to identify the best target. Please check the following dashboard:
+* '''Step 3''': Once the large, and established players were eliminated, companies were compared based on various parameters and rated on the scale of 5 to identify the best target. Please check the following table and dashboard:
 **Number of potential target companies: 6
 {|align="center"

@@ Line 32: / Line 32: @@
 ===Methodology===
-* Step 1: First, list all the players present in Ureteral Stent Market were identified.(The list of companies was retrieved from the FDA site from Registration & Listing database)
+* '''Step 1''': First, list all the players present in Ureteral Stent Market were identified.(The list of companies was retrieved from the FDA site from Registration & Listing database)
 ** Number of companies that were identified in this step: 20
-* Step 2: The second step involved identifying and eliminating companies that are large, and established players or the subsidiaries of the big players in the industry.
+* '''Step 2''': The second step involved identifying and eliminating companies that are large, and established players or the subsidiaries of the big players in the industry.
 **Number of companies eliminated in this step: 14
 **Number of (small) companies of interest left: 6
-* Step 3: Once the large, and established players were eliminated, companies were compared based on various parameters and rated on the scale of 5 to identify the best target. Please check the following dashboard:
+* '''Step 3''': Once the large, and established players were eliminated, companies were compared based on various parameters and rated on the scale of 5 to identify the best target. Please check the following dashboard:
 **Number of potential target companies: 6
@@ Line 49: / Line 49: @@
-* Step 4: Finally, after an in-depth analysis of the potential target companies’ on various parameters, following companies identified to be best possible target companies.
+* '''Step 4''': Finally, after an in-depth analysis of the potential target companies’ on various parameters, following companies identified to be best possible target companies.
-**To improve Product Portfolio : Applied Medical Resources Corp.
+**To improve Product Portfolio : '''Applied Medical Resources Corp.'''
-**To enter in Emerging Markets : Bioteque Corp.
+**To enter in Emerging Markets : '''Bioteque Corp.'''
 ===Company Profile===

@@ Line 25: / Line 25: @@
 *Limiting the severity of competition by increasing the company's market power. A merger can increase the market share of the merged firm. This improves the profitability of the firm due to economies of scale. The bargaining power of the firm vis-à-vis labour, suppliers and buyers is also enhanced. The merged firm can exploit technological breakthroughs against obsolescence and price wars.
-In this research report, researcher considered two following objective of merger and acquisition:
+'''Note:''' In this research report, researcher considered two following objective of merger and acquisition:
 #To Enter in emerging markets

@@ Line 43: / Line 43: @@
 {|align="center"
-|<gflash>1200 900 http://dolcera.com/upload/files/ranking1.swf</gflash>
+|<gflash>1000 750 http://dolcera.com/upload/files/ranking1.swf</gflash>
 |-
 |}

← Older revision		Revision as of 13:31, 16 February 2012
Line 42:		Line 42:
	**Number of potential target companies: 6		**Number of potential target companies: 6

−		+	{\|align="center"
		+	\|<gflash>1200 900 http://dolcera.com/upload/files/Ranking.swf</gflash>
		+	\|-
		+	\|}
		+	<br/>

@@ Line 92: / Line 92: @@
 ====Bioteque Corp.====
-{|border="2" cellspacing="0" cellpadding="4" width="80%" align="center"
+{|border="2" cellspacing="0" cellpadding="4" width="60%" align="center"
 |bgcolor = "#376091" colspan = "2"|<font color="#FFFFFF">'''Bioteque Corp.'''</font>
 |-